
    
      This pilot study was designed in order to evaluate the safety and efficacy of an AmBisomeÂ®
      loading dose regimen, in a weekly administration schedule during the initial phase of
      allogeneic stem-cell transplant and in case of occurrence of GvHD, which are both high risk
      periods as far as severe fungal infection development is concerned.
    
  